Roivant Sciences delivered the quarter that converts it from a pipeline story into a commercial one. The company reported a loss of $0.30 per share for the fiscal second quarter ended September 2026, beating the -$0.52 consensus by 42.3% and improving 25.0% year over year. Revenue was $35.12 million against a $2.6 million consensus, a 1250.8% surprise and 2135.6% year-over-year growth, almost entirely because LISRAYA (brepocitinib) generated $31.0 million in net product revenue in its first five weeks after its August approval in dermatomyositis. The financial beat is real, but it is not the main event. The more consequential development was a run of clinical wins capped by a positive, if narrow, rheumatoid arthritis readout for IMVT-1402. The central tension is that the launch number and the RA result are both strong headlines with caveats attached.

The quality of the quarter deserves scrutiny on two fronts. First, the per-share picture depends on the lens. On a GAAP basis, net loss attributable to Roivant widened to $0.27 per share from $0.17 a year earlier, and loss from continuing operations was $0.29. That deterioration was driven largely by $95.9 million in distributions tied to Genevant equity awards participating in the Moderna settlement proceeds, which added $0.13 per share to the loss. Underlying spending moved in a better direction. Adjusted R&D fell to $137.4 million from $152.9 million as the anti-FcRn franchise was pruned, and adjusted loss from continuing operations narrowed to $133.4 million from $187.8 million. Adjusted SG&A rose to $82.5 million from $72.1 million to support the launch. Second, management acknowledged that specialty-pharmacy stocking helped the $31.0 million figure and declined to split inventory from true demand. It also flagged a modest headwind in the December quarter as that inventory normalizes.

The demand indicators management did share were encouraging. The company cited hundreds of patients on paid drug at September 30, rising to many hundreds by November, along with many hundreds of prescribers and broad payer access so far. That is a sharp departure from the "slow and steady" launch tone set a quarter earlier. The clinical slate reinforced the shift:

• Brepocitinib's CLARITY-1 and CLARITY-2 Phase 3 trials in non-infectious uveitis hit every primary and key secondary endpoint. Median time to treatment failure exceeded 48 weeks versus roughly 12 on placebo, and an sNDA is planned for the first half of calendar 2027.
• Mosliciguat posted a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in PH-ILD, plus a statistically significant 35-meter six-minute-walk gain in a study not powered for that endpoint. Phase 3 is now enrolling, and expansion into other PH forms, IPF and PPF is under evaluation.

IMVT-1402 is where bears have legitimate ammunition. The 600 mg dose met the primary endpoint in the randomized-withdrawal portion of the difficult-to-treat RA trial (92.5% vs. 75.6% ACR20 maintenance, p=0.0139), clearing a bar management itself had warned would be harder. The weaknesses are on the secondary measures and the lower dose:

• The 300 mg arm was indistinguishable from placebo.
• The CDAI and SDAI secondary endpoints did not reach significance.
• The high placebo maintenance rate limits the separation.

FDA alignment on the registrational path is still pending, and the call indicated that timing has drifted from "this fall" to later this year or early next. Meanwhile, the cutaneous lupus study was discontinued after a failed proof-of-concept, and Sjögren's is unlikely to advance beyond the current Phase 2. The FcRn franchise is getting narrower even as it notches a win.

The balance sheet removes financing risk from the debate. Cash and marketable securities stand at $4.2 billion, which management says supports a runway into profitability. The company repurchased roughly $280 million of stock over six months, including $72.5 million this quarter. An additional $1.3 billion from Moderna remains contingent on the Section 1498 appeal, which was argued November 5, so that is an unpriced binary catalyst. The December 9 Investor Day should frame the commercial opportunities in uveitis and RA.

Investor sentiment remains negative but improved meaningfully, rising from -0.28 after the prior report to -0.11. Shares closed at $38.88 before the release, up 17.4% from the open after the August report and 22.5% above the 200-day moving average. Even so, the stock sits 8.5% below the $42.50 52-week high set September 8, just after approval, having pulled back to $33.00 in mid-October before recovering. The market has rewarded the approval but not fully re-rated the stock on the subsequent data flow.

The bottom line is that Roivant's quarter materially de-risked the story: it has a launched product with real early demand, a second brepocitinib indication heading to filing, a standout PH-ILD asset and ample capital. The open questions have shifted from survival and science to execution. Investors will be watching how much of the launch revenue reflects stocking, whether payer access holds, and what the FDA will accept for a single-dose RA program.